Oral small molecule GLP-1 receptor agonist
Lotiglipron 40 mg tablet once daily
LOTI_PO_40MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.41 (0.50 to 10.50) | 0.22 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.75 (1.48 to 9.19) | 0.25 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.73 (1.76 to 7.86) | 0.37 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.41 (1.10 to 9.98) | 0.43 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.72 (0.72 to 3.87) | 0.47 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.56 (0.92 to 6.93) | 0.33 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.97 (0.05 to 15.57) | 0.45 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 52.52 (4.08 to 960) | 0.03 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.51 (0.45 to 12.59) | 0.30 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.33 (1.15 to 9.16) | 0.35 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.77 (1.28 to 5.80) | 0.62 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.92 (0.84 to 10.18) | 0.62 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.29 (0.48 to 3.16) | 0.67 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.87 (0.56 to 5.75) | 0.53 |